Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
NCT06504589 · View on ClinicalTrials.gov ↗
Study Summary
The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to inform CF research, help design CF clinical trials and support the development of new treatments for people with CF who do not take CFTR modulators. Another goal of this study is to learn about research involvement for people with CF who do not take CFTR modulators, engage them in research, and give them an opportunity to learn about what is involved in participating in a CF research study.
Conditions Studied
Study Locations (20)
California
- University of California San Diego — La Jolla
- Childrens Hospital Los Angeles — Los Angeles
- Stanford University Medical Center — Palo Alto
- University of California, San Francisco - Adult Center — San Francisco
- University of California, San Francisco - Peds Center — San Francisco
Florida
- University of Florida — Gainesville
- University of Miami — Miami
- Central Florida Pulmonary Group — Orlando
- Tampa General Hospital — Tampa
Arizona
- Phoenix Children's Hospital — Phoenix
- Tucson Cystic Fibrosis Center — Tucson
Colorado
- Children's Hospital Colorado — Aurora
- National Jewish Health — Denver
Georgia
- Children's Healthcare of Atlanta and Emory University — Atlanta
- Augusta University — Augusta
Alabama
- The Children's Hospital Alabama, University of Alabama at Birmingham — Birmingham
Arkansas
- University of Arkansas for Medical Sciences — Little Rock
Idaho
- Saint Luke's Cystic Fibrosis Center of Idaho — Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2024-09-18 |
| Est. Completion | 2029-08-14 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06504589
The ClinicalTrials.gov registry entry for NCT06504589 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nicole Hamblett, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06504589 reports 20 study locations spanning 10 distinct geographic areas — top geographies include California, Florida, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06504589 about?
NCT06504589 is a clinical study titled "A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators". The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to inf...
What is the current status of trial NCT06504589?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2024-09-18. Estimated completion is 2029-08-14.
What conditions does trial NCT06504589 study?
This clinical trial studies the following conditions: Cystic Fibrosis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT06504589?
This trial is sponsored by Nicole Hamblett, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06504589 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.